US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.01

-0.1150-0.95%

Volume:910.23K

Turnover:10.86M

Market Cap:663.33M

PE:10.17

High:12.19

Open:12.09

Low:11.82

Close:12.12

52wk High:13.59

52wk Low:11.82

Shares:55.25M

Float Shares:55.25M

Volume Ratio:4.79

T/O Rate:1.65%

Dividend:1.42

Dividend Rate:11.80%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.83

PE(LYR):- -

Loading ...

Overview Company News Filings

Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial

Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Brookfield Real Assets Income Fund announces annual shareholder meeting

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

RUSAL’s Yuan-Denominated Bonds Receive ruA+ Rating from Expert RA

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

Brookfield Real Assets Income Fund updates distribution schedule; monthly payout holds at $0.1180 per share for Q2 2026

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/RA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.005,"timestamp":1789501705449,"preClose":12.12,"halted":0,"volume":910233,"delay":0,"changeRate":-0.00948844884488436,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Trading","change":-0.115,"latestTime":"09-15 15:49:13 EDT","open":12.09,"high":12.185,"low":11.82,"amount":10855131.099246,"amplitude":0.030116,"askPrice":12.01,"askSize":200,"bidPrice":12,"bidSize":74,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.12,"dividendRate":0.117993,"postHourTrading":{"tag":"盘后","latestPrice":12.12,"preClose":12.12,"latestTime":"19:30 EDT","volume":22,"amount":267.03,"timestamp":1789428606182,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":4.787395},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.787395,"shares":55254696,"dividePrice":1.4165,"high":12.185,"amplitude":0.030116,"preClose":12.12,"low":11.82,"week52Low":11.82,"pbRate":"0.83","week52High":13.59,"institutionHeld":0,"latestPrice":12.005,"committee":-0.459854,"eps":1.18,"divideRate":0.117993,"volume":910233,"delay":0,"ttmEps":1.18,"open":12.09,"prevYearClose":12.96,"prevWeekClose":12.18,"prevMonthClose":12.55,"prevQuarterClose":12.88,"fiveDayClose":12.52,"twentyDayClose":12.66,"sixtyDayClose":12.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"},{"date":"2026-07-09","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-09","defaultRemindTime":1783603800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-09","currency":"USD","dateTimestamp":1783569600000,"payDate":"2026-07-23"},{"date":"2026-06-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"date":"2026-05-07","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-07","defaultRemindTime":1778160600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-21","payableDate":"2026-05-07","currency":"USD","dateTimestamp":1778126400000,"payDate":"2026-05-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634404286","title":"Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404286","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634404286?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:00","pubTimestamp":1778500800,"startTime":"0","endTime":"0","summary":"Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF (+27%) and APONVIE (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter Healthca","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291812/0/en/Heron-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Reaffirms-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CINV","BK4195","BK4563","BK4211","MEC","RA","HRTX","PFS","BK4161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634880832","title":"Tyler Van Buren Reiterates Buy on Artiva, Citing Strong AlloNK RA Efficacy and Funded Path to Registrational Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634880832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634880832?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:55","pubTimestamp":1778496919,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARTV stock, giving a Buy rating on May 8. Tyler Van Buren has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-artiva-citing-strong-allonk-ra-efficacy-and-funded-path-to-registrational-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-artiva-citing-strong-allonk-ra-efficacy-and-funded-path-to-registrational-trial-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","BK4139","LU1989763005.USD","BK4585","LU0390134368.USD","RA","LU1989773731.SGD","TYL","ARTV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943274","title":"Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943274","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943274?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236260,"startTime":"0","endTime":"0","summary":"Initial AlloNK  clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis  patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents. AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings. U.S. Food and Drug Administration  alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026. Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjgren disease  and systemic sclerosis . autoimmune diseases. The broader autoimmune dataset also included 11","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","ARTV","RA","R","BK4232","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633437715","title":"Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437715","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437715?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236200,"startTime":"0","endTime":"0","summary":"Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/08/3290957/0/en/Artiva-Announces-Positive-Initial-Clinical-Data-with-AlloNK-Across-Multiple-Autoimmune-Diseases-and-FDA-Alignment-to-Initiate-Phase-3-Registrational-Trial-in-Rheumatoid-Arthritis-i.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","RA","BK4006","IE00B66KJ199.SGD","LU2065731478.USD","BK4588","IE0031619046.USD","IE00B7SZL793.SGD","BK4187","LU0963586101.USD","CRS","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145383","title":"Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145383","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145383?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relap","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289800/0/en/Cullinan-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4139","SLE","RA","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","LU0072461881.USD","BK4585","BK4132","BK4006","LU1829250122.USD","AD","BK4161","BK4201","BK4139","KYMR","BPH","EASI","PN","BP","RA","IBD","SID","LU0006061336.USD","LU0320765646.SGD","LU0162691827.USD","BK4588","ATS","BK4096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627745208","title":"Brookfield Real Assets Income Fund announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627745208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627745208?lang=en_us&edition=fundamental","pubTime":"2026-04-14 00:41","pubTimestamp":1776098468,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund set May 21, 2026, for virtual annual shareholder meeting.Shareholders will vote on election of Class I directors.Board nominees include Brian F. Hurley as interested director, Betty A. Whelchel as independent director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brookfield Real Assets Income Fund Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL3RFkLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159983","title":"Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159983","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159983?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:00","pubTimestamp":1775779200,"startTime":"0","endTime":"0","summary":"SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. , a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application  for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis , has been formally accepted by the Center for Drug Evaluation  of the China National Medical Products Administration . This acceptance marks a critical milestone in the company's clinical development in inflammatory skin diseases and represents an important step toward Lynk Pharmaceuticals' transition to commercialization. Zemprocitinib capsules have the potential to provide a new treatment option for patients with atopic dermatitis.Preclinical and clinical studies have demonstrated that zemprocitinib potently and dose-dependently inhibits multiple JAK1-mediated inflammatory signaling pathways, supporting its therapeutic poten","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-nda-acceptance-for-zemprocitinib-by-nmpa-302738518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","RA","CDE.AU","AS","LU1223082196.USD","BK7050","CDE","LU1223083913.SGD","BK4132","LU1223082519.USD","BK4202","BK4099","AD","ZK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625732914","title":"RUSAL’s Yuan-Denominated Bonds Receive ruA+ Rating from Expert RA","url":"https://stock-news.laohu8.com/highlight/detail?id=2625732914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625732914?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:19","pubTimestamp":1775639978,"startTime":"0","endTime":"0","summary":"The latest update is out from United Co RUSAL ( ($HK:0486) ). United Company RUSAL has disclosed that its BO-001P-16 series exchange-traded bonds, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rusals-yuan-denominated-bonds-receive-rua-rating-from-expert-ra?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rusals-yuan-denominated-bonds-receive-rua-rating-from-expert-ra?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623865317","title":"Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623865317","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623865317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:01","pubTimestamp":1774872060,"startTime":"0","endTime":"0","summary":"First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjgren’s disease $75 million private placement strengthens balance sheet and supports telitacicep","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264589/0/en/Vor-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317889","title":"Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317889","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317889?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"First and only dual BAFF/APRIL inhibitor in primary Sjgren’s disease, one of the largest autoimmune diseases without an approved therapyBOSTON, March  30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264556/0/en/Vor-Bio-Doses-First-Patient-in-Global-Phase-3-UPSTREAM-SjD-Registrational-Trial-of-Telitacicept-in-Primary-Sj%C3%B6gren-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","SLE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622742803","title":"Brookfield Real Assets Income Fund updates distribution schedule; monthly payout holds at $0.1180 per share for Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622742803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622742803?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:15","pubTimestamp":1774646158,"startTime":"0","endTime":"0","summary":"Brookfield Real Assets Income Fund set monthly distributions of USD 0.12 per share for April 2026, with a record and ex-dividend date of April 9, 2026 and a payable date of April 23, 2026.May 2026 distribution of USD 0.12 per share has a record and ex-dividend date of May 7, 2026 and a payable date of May 21, 2026.June 2026 distribution of USD 0.12 per share has a record and ex-dividend date of June 11, 2026 and a payable date of June 25, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL869Lpq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","RA","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ","IE00BN0W2W23.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896695","title":"Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896695","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896695?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:02","pubTimestamp":1774555320,"startTime":"0","endTime":"0","summary":"Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026  Progressing enrollment for","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263388/0/en/Kyverna-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LD","BK4006","BK4022","BK4110","RA","IE00B66KJ199.SGD","ACR","LU0963586101.USD","CAR","BK4178","BK4585","BK4139","LU2065731478.USD","IND","HCP","KYTX","BK4230","BK4187","BK4588","CRS","AAN","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":53,"code":"91000000","status":"200"}]}}